Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.42 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | IL1B | P01584 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12506986 | 1.00 | FUCA1 (0.42) | FUCA1MALT1MTNR1AMKNK2GLA | |
| SCHEMBL27410738 | 1.00 | FUCA1 (0.42) | FUCA1MALT1MTNR1AMKNK2GLA | |
| SCHEMBL3085448 | 0.84 | MALT1 (0.42) | MALT1MKNK2ARG1IL1BP2RX7 | |
| SCHEMBL21681172 | 0.84 | MALT1 (0.42) | MALT1MKNK2ARG1IL1BP2RX7 | |
| SCHEMBL21661025 | 0.83 | MALT1 (0.40) | MALT1MTNR1AMKNK2ARG1SLC6A2 | |
| SCHEMBL21661031 | 0.83 | MALT1 (0.40) | MALT1MTNR1AMKNK2ARG1SLC6A2 | |
| Hydrochloric Acid SCHEMBL19056470 | 0.83 | MALT1 (0.41) | MALT1MKNK2ARG1IL1BP2RX7 | |
| SCHEMBL23866590 | 0.82 | MALT1 (0.39) | MALT1MTNR1AMKNK2ARG1IL1B | |
| SCHEMBL23866584 | 0.82 | MALT1 (0.39) | MALT1MTNR1AMKNK2ARG1IL1B | |
| SCHEMBL12413659 | 0.82 | MALT1 (0.39) | MALT1MTNR1AMKNK2ARG1IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125384-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, GMPS, PRKG1 | FUCA1 1118/4885MALT1 1273/4885MTNR1A 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.